Pharmacological characterization of DA‐7503: a novel tau aggregation inhibitor in clinical development for Alzheimer’s disease and primary tauopathies

Our findings suggest that DA-7503, a novel tau aggregation inhibitor with great potencies against pathological 3R and 4R tau isoforms and a favorable non-clinical safety profile, effectively restored motor function and reduced tau aggregates in the JNPL3 mouse model of tauopathy. These results highlight DA-7503's potential as a promising therapeutic candidate for Alzheimer's disease and primary tauopathies, including frontotemporal dementia, progressive supranuclear palsy and corticobasal degeneration. DA-7503 is currently undergoing a phase 1 clinical study.